Abstract
Until late 2010, the vitamin K antagonist warfarin was the only oral anticoagulant approved in the United States for the prevention of thromboembolic events in patients with nonvalvular atrial fibrillation (NVAF) or the prevention and treatment of venous thromboembolism (VTE). With decades of
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
